Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia27-12-2017
27-12-2017
Press Release / Media Release (Revised)
We are pleased to enclose herewith our Press Release relating to US FDA Acceptance of NDA for OTX-101, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,27-12-2017
Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to US FDA Acceptance of NDA for OTX-101, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,27-12-2017
Sun Pharma recalls two batches of diabetic drug from US market
Riomet is an oral diabetes medicine that helps control blood sugar level21-12-2017
Sun Pharma's specialty drugs face competition in US
The Mumbai-based pharma major reported 59% decline in its net profit for the quarter ending September to Rs 912 cr13-12-2017
No major respite for Sun Pharma
The Sun Pharmaceutical stock, after seeing some gains post September quarter results, is now marginally below pre-result levels despite the recent positive news flow. So, what's keeping sentiment low in the counter?First the positive part. The latest development pertains to the restart of supplies of some products to the US by Sun from its key plant in Halol (Gujarat). A Credit Suisse report, referring to IMS data, also indicates that Sun's oncology generics of Gleevac has gained market share sequentially in the December quarter (Q3) so far, on a trailing basis. The Gleevac generics, which has seen competitive pressures post Sun's exclusivity ended in FY17 and contributed $230 million to Sun's FY17 sales, was estimated to see its contribution drop by a third in FY18. So, the news of it gaining market share (19 per cent sequential revenue growth) is positive. This, coupled with Sun's re-entry into key segments such as neurology (Duloxetine, Carbidopa and Levodopa) and ENT (Azelastine ..06-12-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virtuous Finance Pvt Ltd30-11-2017
Sun Pharma shares end marginally higher
Shares of Sun Pharmaceutical Industries Ltd slipped as much as 1.9 per cent to Rs 538.30 as the drugmaker's unit had on Friday issued a voluntary recall of two batches of Riomet, an oral diabetes...27-11-2017
Sun Pharma recalls 2 lots of diabetes drug in US over microbial contamination
Sun Pharma says its US- based subsidiary is recalling two lots of diabetes drug Riomet due to microbial contamination. The product was manufactured by a contract manufacturer25-11-2017
Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to clarification on voluntary recall of Riomet, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,24-11-2017